Continuous Glucose Monitors and GLP-1: Should You Track Your Blood Sugar?

Introduction

Continuous glucose monitors used to be diabetes-only tech. Now they’re sold over the counter at CVS and worn by triathletes, biohackers, and people on semaglutide who want a window into what their pancreas is actually doing.

The question isn’t whether CGMs work. They work. The question is whether the data is useful for someone whose appetite, insulin response, and gastric emptying are all being rewired by a GLP-1. The honest answer is more interesting than the marketing.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Does a CGM Actually Measure During GLP-1 Therapy?

A CGM samples interstitial fluid glucose every 1-5 minutes through a thin filament under the skin. It’s not blood glucose, it’s the fluid bathing your subcutaneous tissue, which lags blood values by about 5-15 minutes.

Quick Answer: Dexcom Stelo and Abbott Lingo got FDA clearance for OTC use in March and June 2024

For people on semaglutide or tirzepatide, the most visible CGM change is flatter postprandial curves. The STEP 2 trial (Davies et al. 2021, Lancet) showed semaglutide 2.4 mg reduced 2-hour postprandial glucose by 1.5 mmol/L in type 2 diabetes. SURPASS-2 (Frias 2021 NEJM) showed tirzepatide 15 mg dropped HbA1c by 2.46% versus 1.86% for semaglutide 1 mg.

That flattening is what a CGM captures in real time. Spikes get smaller. Recovery gets faster. Overnight curves get steadier.

Do You Need a Prescription for a CGM in 2026?

No, not anymore. Dexcom Stelo cleared FDA in March 2024 as the first OTC CGM, followed by Abbott Lingo and Libre Rio in June 2024. All three target non-insulin users who want metabolic data.

Stelo retails around $89 for a 15-day sensor. Lingo runs $49 for two weeks. Libre 3 Plus, still prescription-only, is the same hardware Lingo uses with the consumer firmware swapped out.

The OTC sensors aren’t approved for insulin dosing decisions. They’re approved for trends and patterns. That’s fine for GLP-1 patients who aren’t titrating insulin.

How Accurate Are Over-the-counter CGMs?

Accuracy is measured in MARD, mean absolute relative difference from a reference lab value. Lower is better. The 2024 Dexcom G7 paper (Garg et al., Diabetes Technology & Therapeutics) reported a MARD of 8.2%. Abbott’s Libre 3 reported 7.9% in the same year.

Older first-generation sensors ran 12-15% MARD. Fingerstick meters are 5-10% depending on technique. Lab venous draws are under 3%.

What that means: a sensor reading of 110 mg/dL could be a true 100 or a true 120. For trend tracking, that’s fine. For real diagnosis or insulin dosing, it isn’t.

What Patterns Show up on a CGM During Semaglutide Titration?

The most common pattern during dose escalation is a flattening that happens over weeks, not days. Patients starting at 0.25 mg weekly typically see modest changes in week 1. By week 8, when most reach 1.7 mg, glucose variability drops measurably.

A 2023 paper by Aronne et al. in Diabetes, Obesity and Metabolism tracked CGM data in semaglutide responders and found mean amplitude of glycemic excursion (MAGE) fell by 22% at 16 weeks. Standard deviation of glucose readings dropped 18%.

Hypoglycemia, defined as glucose under 70 mg/dL, is rare in non-diabetic semaglutide users. The STEP 1 trial reported less than 1% incidence. Tirzepatide showed similar safety in SURMOUNT-1.

Can a CGM Help You Understand Reactive Hypoglycemia on GLP-1?

Yes, in select cases. Some patients on semaglutide or tirzepatide describe shakiness, brain fog, or anxiety after meals. A CGM can confirm whether glucose is actually dropping below 70 mg/dL or whether the symptoms are something else.

True postprandial hypoglycemia on GLP-1 monotherapy is uncommon. When it happens, it’s often after high-carb meals followed by delayed gastric emptying, which mismatches insulin release and glucose absorption. The Mayo Clinic Endocrinology group has published case series on this pattern in patients post bariatric surgery, and the mechanism overlaps with GLP-1 effects.

A 14-day CGM trial is enough to capture the pattern if it exists. If glucose stays above 70 even during symptoms, the cause is something else.

Should Non-diabetic Patients on Semaglutide Wear a CGM Long-term?

Probably not. For most non-diabetic patients with obesity, a single 14-day sensor during dose titration gives most of the actionable information. Continuous wear past that point produces diminishing returns and can drive food anxiety.

A 2024 review in JAMA Internal Medicine by Beck and colleagues noted that CGM use in non-diabetic populations correlates with disordered eating behaviors in 12-18% of users. The data feels objective, but the interpretation isn’t always healthy.

If you’re using TrimRx’s compounded semaglutide protocol, a CGM during weeks 4-12 of titration can confirm metabolic response. Past that point, monthly HbA1c plus fasting glucose is usually enough.

Key Takeaway: CGM accuracy MARD sits at 8-10% for newer sensors, compared with under 5% for lab venous draws

What Does a “Good” CGM Trace Look Like on GLP-1 Therapy?

A clean GLP-1 trace shows fasting glucose between 80-95 mg/dL, postprandial peaks under 140 mg/dL, and overnight values between 75-90 mg/dL with low variability. Time-in-range, defined as 70-180 mg/dL, should exceed 95% in non-diabetic users.

For type 2 diabetes patients adding semaglutide or tirzepatide, the AGP (ambulatory glucose profile) target shifts. The American Diabetes Association 2025 standards recommend at least 70% time-in-range for type 2 diabetics on GLP-1 therapy, with under 4% time below 70 mg/dL.

Tirzepatide’s dual GIP/GLP-1 action tends to produce flatter traces than semaglutide alone. SURPASS-CVOT (presented November 2024) reinforced this with HbA1c data, and CGM substudies are forthcoming.

How Does Meal Timing Affect CGM Readings on GLP-1?

Meal timing matters more on GLP-1 than off it, because delayed gastric emptying changes how fast carbs hit the bloodstream. Eating the same meal at 8am versus 8pm can produce dramatically different curves.

A small 2024 crossover study by Hutchison et al. in Diabetes Care found that early time-restricted eating (8am-4pm window) reduced 24-hour glucose AUC by 12% in semaglutide users, compared with late TRE (12pm-8pm) which showed only 4% improvement.

This matches the broader chrononutrition literature. Insulin sensitivity is highest in the morning and falls through the evening. GLP-1 amplifies the morning advantage.

Are There Situations Where CGM Data Could Be Misleading?

Yes. CGMs lag blood glucose by 5-15 minutes, so rapid changes (post-exercise, rapid-acting carbs) can be misread. Pressure-induced false lows are common when sleeping on the sensor side. Acetaminophen interferes with some Dexcom models above 1 gram doses.

Hydration matters too. Severely dehydrated patients can read 10-20 mg/dL high on interstitial fluid. The first 24 hours after sensor insertion are also unreliable, which is why most devices have a 1-2 hour warmup.

Compounded semaglutide users sometimes notice their CGM responds differently after switching from brand-name Wegovy®. That’s usually injection site variability or dose timing, not a true metabolic shift.

Does Insurance Cover CGMs for Non-diabetic GLP-1 Patients?

Rarely. Medicare covers CGMs only for insulin-using diabetics and specific hypoglycemia-prone populations. Commercial insurers follow similar criteria, though some state Medicaid programs (notably California and New York) have expanded coverage in 2025.

For non-diabetic semaglutide patients, OTC CGMs are out-of-pocket. The Stelo subscription runs about $89 every two weeks, which adds up to roughly $2,300 per year if used continuously.

Most patients I’d recommend using a CGM for short cycles, not continuously. A single sensor at the start of TrimRx therapy and another at 6 months is usually enough.

Bottom line: Most non-diabetic users don’t need a CGM, but selective use during titration can be informative

FAQ

How Long Should I Wear a CGM When Starting GLP-1?

Two weeks is enough to capture fasting, postprandial, overnight, and exercise patterns. A single Dexcom Stelo or Abbott Lingo sensor covers this window. If you’re stable and asymptomatic past that point, longer wear adds little.

Can a CGM Detect GLP-1 Non-response?

Indirectly. If postprandial glucose curves don’t flatten over 8-12 weeks of dose escalation, that’s a signal worth bringing to your prescriber. Roughly 13.4% of STEP 1 participants lost less than 5% body weight, and CGM patterns often track with that response.

Do CGMs Work for Tirzepatide Users the Same Way?

Yes. Tirzepatide’s dual action produces flatter glucose curves than semaglutide alone, per SURPASS-2 data. CGM patterns shift the same way, just faster and more pronounced.

Will a CGM Tell Me If My Compounded Semaglutide Is Working?

CGM trends can support that question but not answer it alone. Weight loss, appetite reduction, and HbA1c trends matter more. A flatter glucose curve is a good sign, but a single sensor reading isn’t proof of potency.

Is CGM Data Useful for Adjusting My GLP-1 Dose?

Not directly. Dose decisions are based on weight response, side effects, and HbA1c if applicable. CGM data adds context but shouldn’t drive dose escalation independently. Talk to your TrimRx clinician through the personalized treatment plan messaging.

Can Wearing a CGM Cause Anxiety About Food?

It can. About 1 in 6 non-diabetic users develop heightened food vigilance with continuous CGM wear. If you notice yourself avoiding foods solely because of CGM data, take a break.

What’s the Best CGM for Someone on Compounded Semaglutide?

For OTC use, Dexcom Stelo and Abbott Lingo are equivalent in accuracy. Stelo’s 15-day wear is slightly more convenient than Lingo’s 14 days. Both integrate with smartphone apps without a separate receiver.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

Related Articles

• Weight Loss Surgery vs GLP-1: When Each Makes Sense
• Pediatric GLP-1: Should Teenagers Take Weight Loss Medication?
• SGLT2 Inhibitors + GLP-1: The Emerging Combination Approach
• GLP-1 and Cancer Risk: What Large-Scale Studies Show